Overview

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:
0

Participant gender:
All

Summary

Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Vildagliptin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of vildagliptin for antipsychotic-induced dyslipidemia.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Sadat City University

Treatments:

Vildagliptin

Criteria

Inclusion Criteria:

- Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-Ⅳ) criteria
for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness
was less than 12 months taking only one antipsychotic stable outpatient the total
score of Positive and Negative Syndrome Scale (PANSS)≤60.

Exclusion Criteria:

- liver or renal diseases pregnant or lactating women cardiovascular diseases
hypertension or diabetes mellitus